About this trial

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

Eligibility criteria

Qualifiers

BE patients without dysplasia and with suspected/diagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and/or therapeutic endoscopy

Written informed consent is obtained

Disqualifiers

Patients under the age of eighteen.

Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.

Previous radiation therapy for esophageal cancer

Known immunoglobulin allergy

Trial design

Treatments tested in this trial

  • Avastin
  • Erbitux
  • Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

Treatment groups

25 Participants
are divided into 3 treatment groups

Locations

1
University Medical Center Groningen9713 GZ, GroningenProvincie Groningen, Netherlands

Sponsors and collaborators

University Medical Center Groningen

Lead sponsor